Which antidepressants are associated with increased appetite and weight gain?

Antidepressants Associated with Increased Appetite and Weight Gain

Mirtazapine, paroxetine, and amitriptyline cause the greatest appetite increase and weight gain among antidepressants, with mirtazapine and amitriptyline producing approximately 1.5–1.8 kg of weight gain in controlled trials. 1

Highest-Risk Agents for Weight Gain

Tricyclic Antidepressants (TCAs)

• Amitriptyline is the most potent weight-gain inducer among all TCAs, causing 1.8 kg of weight gain in systematic reviews. 1
• Nortriptyline also produces significant weight gain, though less than amitriptyline. 1
• Imipramine appears weight-neutral and does not increase appetite. 1

Selective Serotonin Reuptake Inhibitors (SSRIs)

• Paroxetine causes the greatest long-term weight gain among all SSRIs, exceeding the weight impact of other agents in this class. 1, 2
• Citalopram and escitalopram show no clinically significant effect on body weight or appetite. 1
• Fluoxetine and sertraline produce modest weight loss during acute treatment (4–12 weeks) but become weight-neutral during maintenance therapy beyond 4 months. 1, 2

Atypical Antidepressants

• Mirtazapine (a noradrenergic and specific serotonergic antidepressant) causes 1.5 kg of weight gain and is strongly associated with appetite stimulation through histamine H1 receptor antagonism. 1
• Mirtazapine ranks between SSRIs and TCAs in terms of weight-gain risk, with effects persisting throughout long-term treatment. 1, 3

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

• Venlafaxine and duloxetine cause slight weight increases over long-term treatment, though evidence for venlafaxine remains limited. 1
• Duloxetine produces 0.34 kg more weight gain than sertraline at 6 months. 4

Weight-Neutral and Weight-Loss Agents

• Bupropion is the only antidepressant that consistently causes weight loss (approximately 1.3 kg) by suppressing appetite and food cravings through dopamine and norepinephrine reuptake inhibition. 1, 5
• Fluoxetine causes 1.3 kg of weight loss during acute treatment but this effect does not persist beyond 4 months. 1

Mechanistic Considerations

• Weight gain from mirtazapine and TCAs occurs primarily through antagonism of histamine H1 receptors in the hypothalamus, which directly stimulates appetite. 5
• Paroxetine's weight-gain mechanism involves serotonin receptor modulation and potential effects on insulin sensitivity, though the exact pathway remains incompletely understood. 6
• Up to 55–65% of patients on long-term antidepressant therapy experience weight gain, contributing to treatment discontinuation and increased risk of obesity and type 2 diabetes. 7

Clinical Decision Algorithm

For patients at risk of weight gain or with existing obesity:

1. First-line: Choose bupropion if clinically appropriate (contraindicated in seizure disorders, eating disorders, or when serotonergic mechanism is required for comorbid anxiety/OCD). 1, 5
2. Second-line: Select fluoxetine or sertraline, which remain weight-neutral long-term. 1, 2
3. Avoid: Paroxetine, mirtazapine, amitriptyline, and nortriptyline in weight-sensitive patients. 1, 2

For patients requiring SNRIs:

• Recognize that both venlafaxine and duloxetine cause modest weight gain; no SNRI offers a weight advantage. 1, 4

For patients already on weight-gain-inducing agents:

• Switch to bupropion, fluoxetine, or sertraline rather than reducing the dose of the current agent, as dose reduction risks relapse without reliably preventing weight gain. 2
• Consider adjunctive metformin (≈1000 mg daily), which produces an average 3 kg weight reduction in patients on weight-gain-inducing antidepressants. 8

Common Pitfalls

• Weight gain from improved appetite due to depression remission must be distinguished from medication-induced weight gain; the former typically stabilizes after mood improvement, while medication-induced gain continues progressively. 7
• Paroxetine is often underestimated for its weight-gain potential because short-term trials (≤12 weeks) may not capture the full effect, which emerges primarily during maintenance treatment. 1, 3
• Mirtazapine's appetite-stimulating effect begins within the first weeks of treatment and persists throughout therapy, making early monitoring essential. 1, 9
• Switching antidepressants solely for weight concerns requires close monitoring for 2–4 weeks to detect early relapse, as discontinuation and initiation of a new agent both carry relapse risk. 8